Evidence map›Paper›PMID 35641597›Full record

ArticleScientific reports2022

A new versatile MR-guided high-intensity focused ultrasound (HIFU) device for the treatment of musculoskeletal tumors.

Paolo Cabras, Pierre Auloge, Fabrice Bing, Pramod Prabhakar Rao, Stéphanie Hoarau, Erik Dumont, Alexandre Durand, Benjamin Maurin, Benoit Wach, Loïc Cuvillon and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Paolo CabrasICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France.
Pierre AulogeDepartment of Interventional Imaging, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Fabrice BingICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France.
Pramod Prabhakar RaoICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France.
Stéphanie HoarauImage Guided Therapy, Pessac, France.
Erik DumontImage Guided Therapy, Pessac, France.
Alexandre DurandAxilum Robotics, Schiltigheim, France.
Benjamin MaurinAxilum Robotics, Schiltigheim, France.
Benoit WachICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France.
Loïc CuvillonICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France.
Elodie BretonICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France.
Afshin GangiICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France.
Jonathan VappouICube, Université de Strasbourg, CNRS, UMR 7357, Strasbourg, France. jvappou@unistra.fr.
Centre National de la Recherche Scientifique · FRUniversité de Strasbourg · FRHôpitaux Universitaires de Strasbourg · FRInstitut de Chirurgie Guidée par l'Image · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic Resonance (MR) Imaging-guided High Intensity focused Ultrasound (MRgHIFU) is a non-invasive, non-ionizing thermal ablation therapy that is particularly interesting for the palliative or curative treatment of musculoskeletal tumors. We introduce a new modular MRgHIFU device that allows the ultrasound transducer to be positioned precisely and interactively over the body part to be treated. A flexible, MR-compatible supporting structure allows free positioning of the transducer under MRI/optical fusion imaging guidance. The same structure can be rigidified using pneumatic depression, holding the transducer rigidly in place. Targeting accuracy was first evaluated in vitro. The average targeting error of the complete process was found to be equal to 5.4 ± 2.2 mm in terms of focus position, and 4.7° ± 2° in terms of transducer orientation. First-in-man feasibility is demonstrated on a patient suffering from important, uncontrolled pain from a bone metastasis located in the forearm. The 81 × 47 × 34 mm

Indexed as

High-Intensity Focused Ultrasound AblationNeoplasms, Connective and Soft TissueThermometryHumansMagnetic Resonance ImagingPain

Identifiers

PMID35641597
PMCPMC9156664
OpenAlexW4282943243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.